•
Dec 31, 2021
Cassava Sciences Q4 2021 Earnings Report
Reported financial results for the full year 2021 and provided clinical and business updates.
Key Takeaways
Cassava Sciences reported a net loss for the full year 2021 of $32.4 million, or $0.82 per share, and has $233.4 million of cash on hand. The company initiated two Phase 3 clinical studies with simufilam in the second half of 2021 and is focused on enrolling over 1,700 patients into the Phase 3 clinical program.
Initiated two Phase 3 clinical studies with simufilam in the second half of 2021.
Phase 3 studies are recruiting patients with mild to moderate Alzheimer’s disease.
Over 200 patients have been screened to date for Phase 3 studies.
Balance sheet has $233.4 million of cash.
Cassava Sciences
Cassava Sciences
Forward Guidance
Cassava Sciences expects to use $25 to $35 million in the first half of 2022, depending on patient enrollment rates and the timing of certain legal expenses.